Estonia - Tiếng Estonia - Ravimiamet

krka, d.d., novo mesto - rivaroksabaan - õhukese polümeerikattega tablett - 10mg 56tk; 10mg 28tk; 10mg 15tk; 10mg 90tk; 10mg 14tk; 10mg 30tk; 10mg 100tk; 10mg 60tk; 10mg 98tk

Estonia - Tiếng Estonia - Ravimiamet

krka, d.d., novo mesto - rivaroksabaan - õhukese polümeerikattega tablett - 15mg 28tk; 15mg 98tk; 15mg 30tk; 15mg 90tk; 15mg 14tk; 15mg 60tk; 15mg 42tk; 15mg 100tk

Estonia - Tiếng Estonia - Ravimiamet

krka, d.d., novo mesto - rivaroksabaan - õhukese polümeerikattega tablett - 20mg 56tk; 20mg 42tk; 20mg 15tk; 20mg 28tk; 20mg 98tk; 20mg 30tk; 20mg 60tk; 20mg 90tk; 20mg 10tk

Estonia - Tiếng Estonia - Ravimiamet

krka, d.d., novo mesto - rivaroksabaan - õhukese polümeerikattega tablett - 2,5mg 28tk; 2,5mg 98tk; 2,5mg 56tk; 2,5mg 100tk; 2,5mg 14tk; 2,5mg 10tk; 2,5mg 30tk

Estonia - Tiếng Estonia - Ravimiamet

zentiva k.s. - rivaroksabaan - kõvakapsel - 10mg 20tk; 10mg 15tk; 10mg 30tk

Estonia - Tiếng Estonia - Ravimiamet

zentiva k.s. - rivaroksabaan - kõvakapsel - 2,5mg 100tk; 2,5mg 28tk; 2,5mg 56tk

Estonia - Tiếng Estonia - Ravimiamet

zentiva k.s. - rivaroksabaan - kõvakapsel - 15mg 14tk; 15mg 42tk; 15mg 28tk; 15mg 100tk; 15mg 30tk

Estonia - Tiếng Estonia - Ravimiamet

zentiva k.s. - rivaroksabaan - kõvakapsel - 20mg 30tk; 20mg 28tk; 20mg 98tk; 20mg 14tk

Liên Minh Châu Âu - Tiếng Estonia - EMA (European Medicines Agency)

accord healthcare s.l.u. - apixaban - venous thromboembolism; stroke; arthroplasty - antitrombootilised ained - prevention of venous thromboembolic events (vte) in adult patients who have undergone elective hip or knee replacement surgery. ennetamine insuldi ja süsteemse emboolia täiskasvanud patsientidel, kellel on mitte-valvulaarne kodade virvendus (nvaf), ühe või mitme riskifaktorid, nagu eelnev insult või mööduv ischaemic attack (tia); vanus ≥ 75 aastat; hüpertensioon; suhkurtõbi; sümptomaatiline südamepuudulikkus (nyha klass ≥ ii). ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel (vt lõik 4. 4 haemodynamically ebastabiilne pe patsientidel). prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischaemic attack (tia); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (nyha class ≥ ii). ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel (vt lõik 4. 4 haemodynamically ebastabiilne pe patsientidel).

Liên Minh Châu Âu - Tiếng Estonia - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroksabaan - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombootilised ained - täiskasvanud patsientidel, kellele tehti plaaniline puusa- või põlveliigese asendamise operatsiooni venoosse trombemboolia (vte) ennetamine. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. (see section 4. 4 for haemodynamically unstable pe patients. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. (see section 4. 4 haemodynamically ebastabiilne pe patsientidel). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 ja 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.